Assembly Biosciences price to free cash flow ASMB

Market value divided by free cash flow over the last twelve months, since 2017.

Today, Oct 23, 2026: n/m; not a meaningful number
Last meaningful: 3.0×; Mar 2025
9-year median: 4.5×
9-year range: 2.6× to 173×
Peer median: 9.4×

Assembly Biosciences' price to free cash flow is not a meaningful number today: free cash flow over the last twelve months was zero, negative or not reported.

It was last meaningful in Mar 2025, at 3.0×.

On the days it had one over the last 9 years, its median was 4.5×, from 2.6× in Jul 2024 to 173× in Oct 2017.

Price to free cash flow over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2025	3.0×	3.0×	4.9×
2024	4.2×	2.6×	5.1×
2023	n/m a value too high to mean anything
2022	n/m a value too high to mean anything
2021	n/m a value too high to mean anything
2020	n/m a value too high to mean anything
2019	n/m a value too high to mean anything
2018	n/m a value too high to mean anything
2017	152×	39.2×	173×

Against its peers

Companies in Drug Manufacturers - General nearest Assembly Biosciences' size, closest first, today.

Company	Price to free cash flow
ASMBAssembly Biosciences	n/m
ARVNArvinas	n/m
PBYIPuma Biotechnology	13.8×
IRWDIronwood Pharmaceuticals	n/m
ZVRAZevra Therapeutics	17.9×
CRMDCorMedix	2.4×
COLLCollegium Pharmaceutical	2.3×
NATRNatures Sunshine Products	11.8×
ABUSArbutus Biopharma	n/m
AMPHAmphastar Pharmaceuticals	7.0×
OMEROmeros	n/m
Peer median	9.4×

What the price to free cash flow tells you

Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.

Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.

More on Assembly Biosciences

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.